๐ Progression in Anti-Aging Technologies: Plasma Exchange, Scientific Possibilities, and Current Limitations
Recent research published in the international journal 《Aging Cell》
offers fresh insights into the field of anti-aging.
Conducted jointly by the Buck Institute for Research on Aging in the US and
the plasma technology company Circulate Health,
this study reports that plasma exchange is effective in reducing
the biological age of individuals to a certain degree
according to small-scale clinical results.
In the study involving 42 participants with an average age of 65,
they were divided into four groups and treated over several months.
In the group that received a combination of plasma exchange and intravenous
immunoglobulin injections, a reduction in biological age of
2.61 years on average was measured, while the group that received therapy
alone saw a reduction of 1.32 years.
This is due to the short-term decrease in the concentration
of aging-related biomarkers in the blood
and positive changes in immune function observed.
Initially approved for treating autoimmune and blood-related
diseases, plasma exchange is a clinical treatment backed by
medical insurance.
However, if performed solely for 'anti-aging' purposes,
it is not covered by insurance, making it costly.
The process separates plasma from blood using external equipment,
removes inflammatory substances and waste,
and replenishes the plasma with saline and proteins before reinfusion
into the body. This approximately two-hour procedure theoretically
lessens aging mechanisms in the body by lowering
the concentration of harmful substances in the blood.
This research holds significant implications for the beauty industry.
The potential to control cellular aging through blood-based therapeutic
technologies is gradually being unveiled.
It could ultimately affect skin elasticity, recovery from damage,
and pigmentation.
The cosmetics industry now faces a turning point, emphasizing
not only surface-level solutions but also embracing internal
physiological changes in research and product development strategies.
Nevertheless, the study has some critical limitations.
First, the limited sample size of 42 participants;
second, the absence of long-term follow-up.
Additionally, sufficient evidence to consistently replicate results
in healthy adults is lacking.
Thus, scientists worldwide are cautiously
approaching these findings.
Kataoun Fomani, a blood expert at the University of Alabama,
warns that unnecessary complications could arise in healthy individuals,
and unverified anti-aging methods might pose risks in
the long run.
Moreover, most existing research is animal-based, while 'forever young'
human trials, driven by desire, continue to be subject
to ethical and scientific debates.
Still, the fact that advanced life sciences technology is
attempting to control the aging mechanisms inside the body,
beyond just the skin barrier, offers
profound insights for cosmetics technology development.
Keeping the skin's homeostasis involves various physiological
mechanisms like immunity, hormones,
and oxidative stress; thus, data from aging research
can scientifically underpin active cosmetic ingredient development.
YURICO5 continually monitors such biology-based information
and researches real solutions that benefit the skin
based on accurate data and safe technologies.
As more large-scale clinical research and long-term follow-up results
accumulate, the influence of such anti-aging treatment
technologies on the cosmetics industry as a whole will grow more significant.
We aim to drive innovation in skin science
by maintaining a balance between foundational research
and consumer-oriented technologies, delivering consistently
proven results.
With continuous advancements in anti-aging technologies and research
within the cosmetics sector, the future of dermatology holds promise. YURICO5 is committed to providing effective skincare products through
technological innovation.
Please do not hesitate to reach out to YURICO5 for any inquiries.
